Dr. Clay Siegall serves as the president, CEO and chairman of Seattle Genetics, the biotechnology company he founded in 1997.
The Washington-based company helps develop targeted cancer therapies to treat patients' unmet needs. Under Dr. Siegall’s leadership, Seattle Genetics has built a diverse flotilla of antibody-based cancer therapies, including ADCETRIS, which was granted accelerated FDA approval in 2011.
Since 1997, Dr. Siegall has served as one of the company’s directors, and he assumed the role of president in 2000. In 2002, he became Seattle Genetics’ CEO, and he has been the board chairman since 2004. During his tenure, the company has raised more than $675 million through public and private offerings, and it went public in 2001.
Prior to his career with Seattle Genetics, Dr. Siegall worked as a principal scientist at Bristol Myers Squibb Pharmaceutical Research Institute. From 1988 to 1991, he was a staff fellow and biotechnology fellow with the National Cancer Institute, National Institutes of Health.
Dr. Siegall has received numerous awards and accolades for his contributions to the scientific community, including being recognized as the Ernst & Young’s Entrepreneur of the Year and the Puget Sound Business Journal’s Dealmaker of the Year. He has authored over 70 publications and holds 15 patents.
Dr. Siegall currently serves on the boards of Mirna Therapeutics, Ultragenyx Pharmaceuticals and Alder Biopharmecuticals. He received his B.S. in zoology from the University of Maryland and his Ph.D. in genetics from George Washington University.
What is Clay B. Siegall's net worth?
The estimated net worth of Clay B. Siegall is at least $73.11 million as of October 2nd, 2023. Dr. Siegall owns 319,636 shares of Seagen stock worth more than $73,113,539 as of April 18th. This net worth estimate does not reflect any other investments that Dr. Siegall may own. Learn More about Clay B. Siegall's net worth.
How do I contact Clay B. Siegall?
Has Clay B. Siegall been buying or selling shares of Seagen?
Who are Seagen's active insiders?
Are insiders buying or selling shares of Seagen?
In the last twelve months, insiders at the biotechnology company sold shares 20 times. They sold a total of 70,520 shares worth more than $14,429,678.66. The most recent insider tranaction occured on November, 10th when CEO David R Epstein sold 10,620 shares worth more than $2,262,166.20. Insiders at Seagen own 25.9% of the company.
Learn More about insider trades at Seagen. Information on this page was last updated on 11/10/2023.
